Intravenous thrombolysis in acute cerebral infarction combined with hyperglycemia under guidance of glycosylated hemoglobin A 1c in the elderly
10.3760/cma.j.cn115354-20210907-00579
- VernacularTitle:糖化血红蛋白指导下的老年急性脑梗死伴血糖超标的阿替普酶静脉溶栓治疗
- Author:
Yawei GU
1
;
Xu CHU
;
Lan ZHAO
;
Lijun WANG
;
Hongxin WANG
Author Information
1. 南开大学附属第四中心医院神经内科,天津 300140
- Keywords:
Acute cerebral infarction;
Diabetes mellitus;
Alteplase;
Glycosylated hemoglobin
- From:
Chinese Journal of Neuromedicine
2021;20(12):1248-1253
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and efficacy of intravenous thrombolysis with recombinant human tissue-type plasminogen activator (rt-PA) in acute cerebral infarction combined with hyperglycemia under the guidance of glycosylated hemoglobin A 1c (HbA1c) level in the elderly. Methods:A retrospective study was performed. Two hundred and sixty-two elderly patients with acute cerebral infarction, admitted to our hospital from January 2018 to June 2021, were chosen in this study. Patients with admission blood glucose of 2.8-22.2 mmol/L and accepted intravenous thrombolysis with standard dose of rt-PA were enrolled into control group; patients with admission blood glucose over 22.2 mmol/L and HbA1c less than 15.59% were enrolled into experimental group. The patients in the experimental group were subdivided into conservative treatment group ( n=63), rt-PA low-dose group (0.6 mg/kg, maximum dose 60 mg, n=67) and rt-PA standard dose group (0.9 mg/kg, maximum dose 90 mg, n=60) according to whether these patients received rt-PA intravenous thrombolysis or not and dosage of rt-PA. The response rate 24 h after treatment and short-term prognosis 7 d after treatment were evaluated by referring to the treatment effectiveness evaluation criteria developed by NINDS clinical trials. The long-term prognosis was evaluated by modified Rankin Scale (mRS) 90 d after treatment. The safety evaluation indexes mainly included incidences of intracranial hemorrhage and complications within 90 d of treatment. Results:(1) The response rate 24 h after treatment showed significant differences among the 4 groups ( P<0.05): that in the control group, rt-PA low-dose group, and rt-PA standard dose group was significantly higher than that in the conservative treatment group ( P<0.05); the good prognosis rate 7 d after treatment showed significant differences among the 4 groups: that in the control group, rt-PA low-dose group, and rt-PA standard dose group was significantly higher than that in the conservative treatment group ( P<0.05). (2) Ninety d after treatment, 59 patients (81.9%), 46 (73.0%), 53 (79.1%), and 46 (76.7%) in the control group, conservative treatment group, rt-PA low-dose group, and rt-PA standard dose group had good prognosis, without significant differences among each group ( P>0.05). (3) There was significant difference in the incidence of cerebral hemorrhage within 90 d of treatment among the 4 groups ( P<0.05): that in the rt-PA standard dose group and rt-PA low-dose group was significantly higher than that in the control group and conservative treatment group, and that in the rt-PA standard dose group was significantly higher than that in the rt-PA low-dose group ( P<0.05). Seven patients (9.7%), 8(12.7%), 5(7.5%), and 13(21.7%) in the control group, conservative treatment group, rt-PA low-dose group, and rt-PA standard dose group had extracranial complications: the incidence of extracranial complications in the rt-PA low-dose group was significantly lower than that in the rt-PA standard-dose group ( P<0.05). There were 7 kinds of residual neurological dysfunction in 4 groups within 90 d of treatment, among which, numbness, weakness and speech impairment were the most common. Conclusion:Elderly acute cerebral infarction patients with admission blood glucose over 22.2 mmol/L can receive rt-PA treatment when HbA1c is less than 15.59%, and 0.6 mg/kg dosage is recommended.